Join to View Full Profile
121 Macnider BuildingUniversity Of North Carolina Department Of MedicineChapel Hill, NC 27599
Phone+1 919-843-5996
Fax+1 919-966-5775
Are you Dr. Bartlett Pandite?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Arundathy (Pandite) Bartlett Pandite, MD is a hematologist in Chapel Hill, North Carolina. She is currently licensed to practice medicine in North Carolina.
Education & Training
St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
Univ Liverpool- Fac MedClass of 1983
Certifications & Licensure
NC State Medical License 2007 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
Journal for Immunotherapy of Cancer. 2025-01-11 - 5 citationsPazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.Cora N Sternberg, Ian D Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee
Journal of Clinical Oncology. 2023-04-10 - 288 citationsAntitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T Cells in Synovial SarcomaSandra P. D'Angelo, Luca Melchiori, Melinda S. Merchant, Donna Bernstein, John Glod
Cancer Discovery. 2018-06-11
Press Mentions
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 Mutant AML PatientsJune 14th, 2024- Key Takeaways from Phase 1B Trial of SL-172154 in Frontline HR-MDS and TP53m AMLMay 14th, 2024
